Key points are not available for this paper at this time.
Abstract
Apilimod was well-tolerated but did not demonstrate efficacy over placebo in patients with active CD.
问 AI
Like
Bookmark
Share
View Full Paper
问 AI
Like
Bookmark
Share
View Full Paper
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease | Synapse